Under the terms of the agreement, Akili will become a wholly owned subsidiary of Virtual Therapeutics and Akili shareholders will receive $0.4340 in cash for each common share they hold.
Under the terms of the agreement, Akili will become a wholly owned subsidiary of Virtual Therapeutics and Akili shareholders will receive $0.4340 in cash for each common share they hold.
Sign in to your account